TScan Therapeutics

SOC + TSC-100 (TSCAN-001) is a Phase 1 small-molecule program sponsored by TScan Therapeutics for acute myeloid leukemia (AML). The program combines amlexanox (a phosphodiesterase 4 inhibitor approved as APHTHASOL for dental use) and antazoline phosphate (a histamine H1 receptor antagonist approved as VASOCON-A for ophthalmic use) in a novel combination approach. As of April 2026, the program remains in active Phase 1 development. The mechanism of action, specific target engagement, and clinical rationale for combining these two repurposed agents in AML have not been disclosed. TScan's strategy appears to leverage existing approved small molecules in a new indication, potentially accelerating development timelines. No partnership arrangements or licensing terms have been publicly announced. The program is registered under NCT05473910, indicating active patient enrollment or data generation. Peak sales projections, consensus positioning, and expected regulatory milestones remain undisclosed.

Acute myeloid leukemia remains a serious hematologic malignancy with significant unmet medical need, particularly in elderly and treatment-resistant populations. The competitive landscape for AML includes multiple approved agents (venetoclax, olutasidenib, gilteritinib) and numerous Phase 3 candidates, indicating robust commercial interest but also a crowded market. TScan's approach of repurposing approved small molecules for AML may offer advantages in regulatory pathway acceleration and manufacturing scale-up if clinical efficacy is demonstrated. The combination of a PDE4 inhibitor and H1 antagonist represents a non-traditional mechanism in oncology, suggesting potential for differentiated activity or tolerability. However, without disclosed mechanistic rationale or preliminary efficacy signals, the clinical relevance and commercial potential remain uncertain. The Phase 1 stage indicates early-stage development; progression to Phase 2 would require demonstration of acceptable safety and preliminary activity. Market penetration will depend on comparative efficacy, safety profile, and positioning relative to established standards of care and emerging competitors in Phase 3 development.

Program Composition: SOC + TSC-100 combines two repurposed approved drugs.

• Amlexanox (APHTHASOL): Phosphodiesterase 4 inhibitor; approved by FDA (NDA020511, NDA021727) for dental use; route of administration: dental.
• Antazoline Phosphate (VASOCON-A): Histamine H1 receptor antagonist; approved by FDA (NDA018746) for ophthalmic use; route of administration: ophthalmic.

Modality: Small-molecule combination. Indication: Acute myeloid leukemia. Development Stage: Phase 1. Sponsor: TScan Therapeutics. Patent Status: Not yet disclosed. Related Therapies in AML: Venetoclax (BCL2 inhibitor), olutasidenib (IDH1 inhibitor), gilteritinib (FLT3 inhibitor), ziftomenib (DOT1L inhibitor).

FDA Status: SOC + TSC-100 is in Phase 1 development; no IND, BLA, or NDA submissions have been disclosed. The component drugs have existing FDA approvals: amlexanox approved for dental use (NDA020511, NDA021727 under sponsor ULURU); antazoline phosphate approved for ophthalmic use (NDA018746 under sponsor NOVARTIS). Use of approved drugs in a new indication and combination does not automatically confer regulatory advantages but may facilitate IND application and Phase 1 initiation. EMA, PMDA, NMPA Status: Not yet disclosed. Regulatory Pathway: Expected to follow standard Phase 1→2→3 pathway for oncology; breakthrough therapy or accelerated approval designations have not been announced. No regulatory interactions, guidance meetings, or expedited review designations are documented in the provided facts.

Strategic Positioning: TScan's approach leverages two FDA-approved small molecules with established safety profiles in non-oncology indications, potentially reducing development risk and accelerating regulatory timelines if efficacy is demonstrated in AML. Repurposing approved drugs can lower development costs and manufacturing complexity compared to de novo drug discovery.

Competitive Implications: The AML market is increasingly crowded with approved targeted therapies and multiple Phase 3 candidates. TScan's combination approach must differentiate on efficacy, safety, or activity in resistant populations to gain market share. The mechanistic rationale for combining PDE4 inhibition and H1 antagonism in AML remains undisclosed, limiting assessment of competitive advantage.

Clinical Development Catalysts: Progression from Phase 1 to Phase 2 will require demonstration of acceptable safety and preliminary evidence of anti-leukemic activity. Publication of Phase 1 data, including dose escalation results, pharmacokinetics, and any early efficacy signals, will be critical for investor and clinical community confidence. Regulatory feedback on Phase 2 trial design and endpoints will inform competitive positioning.

Future Milestones: Expected catalysts include Phase 1 data readout, Phase 2 initiation, interim efficacy data, and potential regulatory interactions. No timelines for these milestones have been disclosed.